KNK437 Downregulates Heat Shock Protein 27 of Pancreatic Cancer Cells and Enhances the Cytotoxic Effect of Gemcitabine

Authors:
  • YKYasuhiro Kuramitsu
    Yasuhiro Kuramitsu
  • SRShomei Ryozawa
    Shomei Ryozawa
  • KYKanako Yoshida
    Kanako Yoshida
  • TTToshiyuki Tanaka
    Toshiyuki Tanaka
  • SMSayaka Mori-Iwamoto
    Sayaka Mori-Iwamoto
  • SMShin-Ichiro Maehara
    Shin-Ichiro Maehara
  • YMYoshihiko Maehara
    Yoshihiko Maehara
  • ISIsao Sakaida
    Isao Sakaida
  • KNKazuyuki Nakamura
    Kazuyuki Nakamura

Abstract
Background: Our previous proteomic study demonstrated that expression of heat shock protein 27 (HSP27) is upregulated in gemcitabine (GEM)-resistant pancreatic cancer cells and that it suppressed the cytotoxic effect of GEM on the cells. This report describes the benefits of a treatment strategy combining the HSP inhibitor KNK437 with GEM for GEM-resistant pancreatic cancer cells. Methods: We used 2 human pancreatic cancer cell lines, GEM-sensitive KLM1 and GEM-resistant KLM1-R. KLM1-R was treated with KNK437, and we examined the expression of HSP27 by Western blotting. The cytotoxicity of GEM and KNK437 for KLM1-R was investigated by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay. Results: The expression of HSP27 in KLM1-R was dramatically reduced by KNK437. In addition, the in vitro antitumor cytotoxic effect of GEM on KLM1-R was enhanced by combination treatment with KNK437 compared to GEM alone. Conclusion: This study supports the potential therapeutic benefits of a treatment strategy combining KNK437 with GEM.